Atox Bio is a late-stage biotechnology company that develops immunotherapies for critically ill patients. Atox Bio's lead product, reltecimod, is being developed to treat necrotising soft tissue infection (NSTI) more commonly known as ‘flesh eating bacteria’, for which no current therapy exists. Reltecimod, is a novel peptide that modulates the body’s severe acute immune response and lowers morbidities and mortality.
NSTI’s are rapidly progressing infections that result in significant tissue destruction and systemic disease leading to multiple organ dysfunction, failure and death.
Mentions in press and media 3